The Personalised Medicine Commission (ComPerMed) is a committee which brings together Belgian scientific expertise in this area. DNA sequencing using the "Next -Generation Sequencing" (NGS) technique makes it possible to personalise treatment and optimise the management of patients with cancer. Applications of personalised medicine are currently seen mainly in the areas of oncology and haemato-oncology.
The creation of ComPerMed in late 2015 by the Cancer Centre is one of the concrete actions mentioned in the roadbook ("Personalised Medicine" roadbook, introduction to Next-Generation Sequencing in routine diagnosis in oncology and haemato-oncology) which was published in October 2015 to respond to the rapid development and technical complexity of NGS analyses.
The key objectives of ComPerMed are:
- to develop technical guidelines to permit quality assurance for the molecular tests, and specifically for the NGS tests, used in oncology and haemato-oncology.
- to define which molecular biomarkers (DNA) must, as a minimum, be analysed by NGS for each type of tumour (solid and haematological). The choice of these genes is based on the scientific evidence of its specific clinical use for that specific tumour type.
- to work out, for each type of tumour, good clinical practices in the form of an algorithm showing the various molecular tests to be carried out in routine clinical practice.
- to evaluate new "omics" technologies in the context of clinical use in (haemato)-oncology.